Sorry, you need to enable JavaScript to visit this website.
CLOSE
MENU
Seikagaku Announces Revision of Full-Year Consolidated Earnings Forecast for the Fiscal Year Ending March 31, 2027
11.10.2026
サブ-ナビゲーション
TOP
現在位置:
News Release
Who we are
”Hyaluronic Acid” Expedition
Hyaluronic Acid - I am also in your home
Hyaluronic Acid- Everywhere in your body
Hyaluronic Acid- This is what I am!
Hyaluronic Acid- How I work in your body
Story Time
What is Glycoscience
Are glucides sweet?
Glycoscience in one minute
Introduction to the Glycoscience
Part 1 Invitation to Glycoscience
Part 2 Fertilization
Part 3 Source of Energy
Part 4 Extracellular matrix 1
Part 5 Extracellular matrix 2
Part 6 Cell proliferation and differentiation
Part 7 Blood type
Part 8 Cancer
Part 9 Viral infection
Part 10 Applications and Developments
Management Policy
Message from President
Mid-term Management Plan
Profit Distribution Policies
Corporate Governance
Highlights
Summary of Financial Results
Financial Trend
Long-term Trend and Topics
Research & Development Pipeline
Stock Information
Stock Information
Profit Distribution
Ordinary General Meeting of Shareholders
Our R&D
R&D Basic Policy
R&D Structure
R&D Pipeline
Process of new drug development
Intellectual Property
Sustainability
Sustainability Management
Materiality
Stakeholder Engagement
Environmental Policy
Environmental Impact Reduction Initiatives
Initiatives for Biodiversity
Information Disclosure Based on the TCFD Recommendations
Social Contribution Activities
Human Resource Development
Diversity and Work-Life Balance
Corporate Governance
Compliance
Risk Management
Our Policy
ESG Data Book
External Evaluations
Investors
News Release
What's New
Management Policy
Message from President & CEO
Mid-term Management Plan
R&D Pipeline
Profit Distribution Policies
Business Risks
Highlights
Business Performance
Business Performance（Quarter）
Cash Flow
Business Performance Data Download
IR Library
Summary of Financial Results
Presentation Material
Corporate Report
IR Schedule
Shareholder Information
Stock Information
Shareholder Composition
Profit Distribution
General Meeting of Shareholders
Analyst Coverage
Stock Price
IR E-mail Alert
Our Company
Greeting
Corporate Philosophy
History
Corporate Profile
Member of the Board
Organizational Chart
Corporate Governance
Compliance
Risk Management
Information Security
Value Creation Process
Social Contribution Activities
Business Activities
Business Segment
Products
Pharmaceuticals and Medical Devices
Bulk Products
LAL Business
Contract development and manufacturing organization (CDMO)
Production
Quality Compliance
Privacy Policy
Terms of Use
Sitemap
Seikagaku Announces Revision of Full-Year Consolidated Earnings Forecast for the Fiscal Year Ending March 31, 2027
11.10.2026